Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134 Newsletter: http://autoimmunedevreport.com/
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Evidence Based Rheumatology Podcast
E138: Dapirolizumab for SLE (PHOENYCS-GO)
E137: Obexelimab in IgG4-RD (INDIGO)
E136: Secukinumab in PMR (REPLENISH)
E134: Brepocitinib in Dermatomyositis (VALOR)
Get summaries like this every morning.
Free AI-powered recaps of The Evidence Based Rheumatology Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.